Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cathy B Moelans

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Journal of the National Cancer Institute|March 17, 2011
Re: How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gearCathy B Moelans, Paul J van Diest
Journal of Clinical Pathology|October 28, 2011
HER2 testing recommendations in the UK: dual- or single-colour in-situ hybridisation?Cathy B Moelans, Paul J van Diest
Journal of Clinical Pathology|January 15, 2014
CEP17 copy number increase does not indicate polysomy 17Cathy B Moelans, Paul J van Diest
The Lancet. Oncology|September 10, 2011
Implications of rarity of chromosome 17 polysomy in breast cancerCathy B Moelans, Jorge S Reis-Filho, Paul J van Diest
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in metastatic breast cancer--letterCathy B Moelans, Roel A de Weger, Paul J van Diest
Breast Cancer Research and Treatment|September 18, 2009
Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplificationCathy B Moelans, Roel A de Weger, Paul J van Diest
Methods in Molecular Biology (Clifton, N.J.)|July 16, 2011
Amplification testing in breast cancer by multiplex ligation-dependent probe amplification of microdissected tissueCathy B Moelans, Roel A de Weger, Paul J van Diest
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology|May 6, 2010
Multiplex ligation-dependent probe amplification to detect HER2 amplification in breast cancer: new insights in optimal cut-off valueCathy B Moelans, Roel A de Weger, P J van Diest
The Journal of Pathology|June 29, 2011
Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancerCathy B Moelans, Anoek H J Verschuur-Maes, Paul J van Diest
Oncotarget|December 1, 2016
Unravelling site-specific breast cancer metastasis: a microRNA expression profiling studyWillemijne A M E Schrijver, Paul J van Diest, , et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Journal of the National Cancer Institute|March 17, 2011
Re: How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gearCathy B Moelans, Paul J van Diest
Journal of Clinical Pathology|October 28, 2011
HER2 testing recommendations in the UK: dual- or single-colour in-situ hybridisation?Cathy B Moelans, Paul J van Diest
Journal of Clinical Pathology|January 15, 2014
CEP17 copy number increase does not indicate polysomy 17Cathy B Moelans, Paul J van Diest
The Lancet. Oncology|September 10, 2011
Implications of rarity of chromosome 17 polysomy in breast cancerCathy B Moelans, Jorge S Reis-Filho, Paul J van Diest
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in metastatic breast cancer--letterCathy B Moelans, Roel A de Weger, Paul J van Diest
Breast Cancer Research and Treatment|September 18, 2009
Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplificationCathy B Moelans, Roel A de Weger, Paul J van Diest
Methods in Molecular Biology (Clifton, N.J.)|July 16, 2011
Amplification testing in breast cancer by multiplex ligation-dependent probe amplification of microdissected tissueCathy B Moelans, Roel A de Weger, Paul J van Diest
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology|May 6, 2010
Multiplex ligation-dependent probe amplification to detect HER2 amplification in breast cancer: new insights in optimal cut-off valueCathy B Moelans, Roel A de Weger, P J van Diest
The Journal of Pathology|June 29, 2011
Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancerCathy B Moelans, Anoek H J Verschuur-Maes, Paul J van Diest
Oncotarget|December 1, 2016
Unravelling site-specific breast cancer metastasis: a microRNA expression profiling studyWillemijne A M E Schrijver, Paul J van Diest, , et al.
Pageof 8